Heterologous Vaccination with SARS-CoV-2 Spike saRNA Prime followed by DNA Dual-Antigen Boost Induces Robust Antibody and T-Cell Immunogenicity against both Wild Type and Delta Spike as well as Nucleocapsid Antigens

Adrian Rice^{1¶}, Mohit Verma^{1¶}, Emily Voigt^{2¶}, Peter Battisti², Sam Beaver², Sierra Reed², Kyle
Dinkins¹, Shivani Mody¹, Lise Zakin¹, Peter Sieling¹, Shiho Tanaka¹, Brett Morimoto¹, Wendy
Higashide¹, C. Anders Olson¹, Elizabeth Gabitzsch¹, Jeffrey T. Safrit¹, Patricia Spilman¹, Corey
Casper^{2,3}, Patrick Soon-Shiong^{1*}

¹ImmunityBio, Inc., 9920 Jefferson Blvd., Culver City, CA, 90232 USA

²Infectious Disease Research Institute (IDRI), 1616 Eastlake Ave. East, Seattle, WA, 98102,
USA

³Departments of Medicine and Global Health, University of Washington, 1959 Pacific Street NE,
Seattle, WA, 98195, USA

*Corresponding author Patrick Soon-Shiong: Patrick@Nantworks.com

¶These authors contributed equally

ABSTRACT

We assessed if immune responses are enhanced in CD-1 mice by heterologous vaccination with two different nucleic acid-based COVID-19 vaccines: a next-generation human adenovirus serotype 5 (hAd5)-vectored dual-antigen spike (S) and nucleocapsid (N) vaccine (AdS+N) and a self-amplifying and -adjuvanted S RNA vaccine (SASA S) delivered by a nanostructured lipid carrier. The AdS+N vaccine encodes S modified with a fusion motif to increase cell-surface expression. The N antigen is modified with an Enhanced T-cell Stimulation Domain (N-ETSD) to direct N to the endosomal/lysosomal compartment to increase the potential for MHC class I and II stimulation. The S sequence in the SASA S vaccine comprises the D614G mutation, two prolines to stabilize S in the prefusion conformation, and 3 glutamines in the furin cleavage region to increase cross-reactivity across variants. CD-1 mice received vaccination by prime > boost homologous and heterologous combinations. Humoral responses to S were the highest with any regimen including the SASA S vaccine, and IgG against wild type S1 and Delta (B.1.617.2) variant S1 was generated at similar levels. An AdS+N boost of an SASA S prime enhanced both CD4+ and CD8+ T-cell responses to both S wild type and S Delta peptides relative to all other vaccine regimens. Sera from mice receiving SASA S homologous or heterologous vaccination were found to be highly neutralizing of all pseudovirus tested: Wuhan, Delta, and Beta strain pseudoviruses. The findings here support the clinical testing of heterologous vaccination by an SASA S > AdS+N regimen to provide increased protection against COVID-19 and SARS-CoV-2 variants.

INTRODUCTION

Impressive efforts of the scientific and pharmaceutical community have resulted in the design, testing and successful deployment of several COVID-19 vaccines that have shown high levels of efficacy.¹⁻⁵ Nonetheless, SARS-CoV-2 viral variants have continued to emerge and spread throughout the globe, particularly in areas where vaccination rates are low or vaccines are unavailable.

To address the need for a vaccine regimen that would be highly efficacious against predominating and emerging variants that may be made available in currently underserved areas and nations, and leverages the resilience of cell-mediated immunity against variants, we previously developed a next-generation human adenovirus serotype 5 (hAd5)-vectored dual-antigen spike (S) plus nucleocapsid (N) vaccine (AdS+N).^{6,7} This vaccine encoding Wuhan strain or ‘wild type’ (wt) SARS-CoV-2 S modified with a fusion sequence (S-Fusion) to enhance cell-surface expression^{6,7} as well as N modified with an Enhanced T-cell Stimulation Domain (N-ETSD)⁸ to increase the potential for MHC class I and II stimulation⁹⁻¹¹ has been shown to elicit humoral and T-cell responses in mice,⁷ non-human primates (NHP),⁶ and participants in Phase 1b trials.⁸ The Ad5S+N vaccine given as a subcutaneous (SC) prime with two oral boosts protected NHP from SARS-CoV-2 infection⁶ and a single prime vaccination of clinical trial participants generated T-cell responses that were sustained against a series of variant S peptide sequences, including those for the B.1.351, B.1.1.7, P.1, and B.1.426 variants.⁸

Despite the promising findings with the AdS+N vaccine candidate, we wish to continue to investigate vaccine regimens with the potential to maximize immune responses – both humoral and cellular. One such approach is by heterologous vaccination utilizing two nucleic acid-based vaccines: ImmunityBio’s hAd5 vectored DNA vaccine and the Infectious Disease Research

Institute's (IDRI's) RNA-based vaccine.¹² Heterologous vaccination using vaccine constructs expressing the same or different antigens vectored by different platforms, specifically combinations of RNA- and adenovirus-based vaccines has previously been reported to significantly increase immune responses.^{13,14}

To assess the potential for enhanced immune responses by heterologous vaccination, we tested prime > boost combinations of the AdS+N vaccine with a self-amplifying and self-adjuvanted S(wt) RNA-based vaccine (SASA S) delivered in a nanostructured lipid carrier (NLC).^{15,16} The NLC stabilizes the self-amplifying RNA¹⁷⁻¹⁹ and delivers it to cells wherein it is amplified and the S protein expressed. The S sequence in the SASA S vaccine comprises a codon-optimized sequence with the D614G mutation²⁰ that increases SARS-CoV-2 susceptibility to neutralization,²¹ a diproline modification to stabilize S in the pre-fusion conformation that increases antigenicity,²² and a tri-glutamine (3Q) repeat in the furin cleavage region to broaden immune responses against variants.²³ Preclinical studies of the SASA S vaccine have demonstrated the vaccine elicited vigorous antigen-specific and virus-neutralizing IgG and polyfunctional CD4+ and CD8+ T-cell responses after both a prime and boost in C57Bl/6 mice.

In this work, the two aforementioned vaccines were tested by homologous prime > boost delivery of each as compared to heterologous delivery regimens with an alternating order: AdS+N > SASA S and SASA S > AdS+N. The findings reported here support our hypothesis that heterologous vaccination with the SASA S and AdS+N vaccines would enhance immune responses, particularly T-cell responses.

Both CD4+ and CD8+ T-cell responses were enhanced by heterologous vaccination, with CD4+ interferon- γ (IFN- γ) production in response to both S(wt) peptides being higher with the SASA S prime > AdS+N boost combination as compared to all other groups. Notably, CD4+ and

CD8⁺ T cells were equally responsive to S(wt) and S(Delta) peptides and responses of T cells from SASA S > AdS+N to S(Delta) were also the highest of the groups.

Findings were similar for unselected T cells in ELISpot analyses, which again revealed the SASA S > AdS+N combination resulted in significantly higher IFN- γ secretion by T cells in response to both S(wt) peptides than all other groups.

We further demonstrate that all combinations that included the SASA S vaccine elicited the greatest anti-full length (FL) S wild type (wt), anti-S1(wt) and – importantly- anti-Delta variant (B.1.617.2) S1 IgG responses. Regimens comprising the SASA S vaccine also generated sera that showed high and similar capability to neutralize Wuhan, Delta, and Beta strain pseudovirus.

As expected, anti-N IgG antibodies and T-cell responses to N peptides were seen only for vaccine combinations that delivered the N antigen and were very similar among groups receiving the AdS+N vaccine in any order.

METHODS

The hAd5 [E1-, E2b-, E3-] platform and constructs

For studies here, the next generation hAd5 [E1-, E2b-, E3-] vector was used to create viral vaccine candidate constructs. ⁶ This hAd5 [E1-, E2b-, E3-] vector is primarily distinguished from other first-generation [E1-, E3-] recombinant Ad5 platforms ^{24,25} by having additional deletions in the early gene 2b (E2b) region that remove the expression of the viral DNA polymerase (pol) and in pre terminal protein (pTP) genes, and its propagation in the E.C7 human cell line. ²⁶⁻²⁹

The AdS+N vaccine expresses a wild type spike (S) sequence [accession number YP009724390] modified with a proprietary ‘fusion’ linker peptide sequence as well as a wild type nucleocapsid (N) sequence [accession number YP009724397] with an Enhanced T-cell

Stimulation Domain (ETSD) signal sequence to direct translated N to the endosomal/lysosomal pathway⁸ as described in Gabitzsch *et al.*, 2021.⁶

The SASA S vaccine comprises an saRNA replicon composed of an 11.7 kb construct expressing the SARS-CoV-2 Spike protein, along with the non-structural proteins 1-4 derived from the Venezuelan equine encephalitis virus (VEEV) vaccine strain TC-83. The Spike RNA sequence is codon-optimized and expresses a protein with the native sequence of the original Wuhan strain plus the dominant D614G mutation, with the prefusion conformation-stabilizing diproline (pp) mutation (consistent with other vaccine antigens) and replacement of the furin cleavage site RRAR sequence with a QQAQ sequence, as shown in Figure 1.

Fig. 1 The saRNA(D614G)-2P-3Q-NLC (SASA S) vaccine. The SASA S vaccine comprises an saRNA replicon backbone consisting of the non-structural protein (nsPs) 1-4 derived from the Venezuelan equine encephalitis virus (VEEV) vaccine strain TC-83 and an independent open reading frame under the control of a subgenomic promoter sequence that contains Wuhan sequence S with a diproline (pp) mutation and a QQAQ furin cleavage site sequence.

The RNA is generated by T7 promoter-mediated *in vitro* transcription using a linearized DNA template. *In vitro* transcription is performed using an in house-optimized protocol^{12,30,31} using T7 polymerase, RNase inhibitor, and pyrophosphatase enzymes. DNA plasmid is digested with DNase I and the RNA is capped by vaccinia capping enzyme, guanosine triphosphate, and S-adenosyl-methionine. RNA is then purified from the transcription and capping reaction components by chromatography using a CaptoCore 700 resin (GE Healthcare) followed by diafiltration and concentration using tangential flow filtration into 10 mM Tris buffer. The RNA material is terminally filtered with a 0.22 µm polyethersulfone filter and stored at -80°C until use.

The RNA-stabilizing nanostructured lipid carrier (NLC) is comprised of particles with a hybrid liquid and solid oil core, which provides colloidal stability³² Non-ionic hydrophobic and hydrophilic surfactants help maintain a stable nanoparticle droplet, while a cationic lipid provides the positive charge for electrostatic binding of RNA. That binding on the surface of the nanoparticles protects RNA from degradation by RNases and allowing delivery to cells that will express the S antigen.

NLC is manufactured by mixing the lipids in an oil phase, dissolving the Tween 80 in citrate buffer aqueous phase, and homogenizing the two phases by micro-fluidization. The resulting emulsion is sterile-filtered and vialled, and reconstituted in an appropriate buffer before use.

Murine immunization and blood/tissue collection

The design of vaccination study performed using CD-1 mice is shown in Figure 2.

Fig. 2 Study design and vaccine description. (A) CD-1 mice received prime vaccination on Day 0 after blood collection and the boost on Day 21; mice were euthanized and tissues/blood collected on Day 35. (B) The various combinations of prime > boost are shown, including: AdS+N homologous; saRNA(D614G-2P-3Q)-NLC (SASA S) homologous; Ad5S+N prime, SASA S boost; and SASA S prime, AdS+N boost. Untreated mice were used as controls. All were n = 7 with the exception of untreated n = 4 and SASA S homologous n = 6. The color code for each group is shown.

All *in vivo* experiments described were carried out in strict accordance with good animal practice according to NIH recommendations. All procedures for animal use were approved by the IACUC Committee at Omeros, Inc. (Seattle, WA, USA) and under an approved protocol.

CD-1 female mice (Charles River Laboratories) 6-8 weeks of age were used for immunological studies performed at the vivarium facilities of Omeros Inc. (Seattle, WA). The adenovirus-vectored vaccines were administered by subcutaneous (SC) injections at the indicated doses in 50 μ L ARM buffer (20 mM Tris pH 8.0, 25 mM NaCl, with 2.5% glycerol). The SASA S vaccine was administered intramuscularly (IM) in 10% sucrose 5 mM sodium citrate solution at a dose of 10 μ g.

On the final day of each study, blood was collected via the submandibular vein from isoflurane-anesthetized mice for isolation of sera using a microtainer tube and then mice were euthanized for collection of spleens. Spleens were removed from each mouse and placed in 5 mL of sterile media (RPMI/HEPES/Pen/Strep/10% FBS). Splenocytes were isolated³³ within 2 hours of collection and used fresh or frozen for later analysis.

Intracellular cytokine stimulation (ICS)

ICS assays were performed using 10⁶ live splenocytes per well in 96-well U-bottom plates. Splenocytes in RPMI media supplemented with 10% FBS were stimulated by the addition of pools of overlapping peptides spanning the SARS-CoV-2 S protein (both wild type, wt, or Delta sequence) or N antigens at 2 μ g/mL/peptide for 6 h at 37°C in 5% CO₂, with protein transport inhibitor, GolgiStop (BD) added two hours after initiation of incubation. The S peptide pool (wild type, JPT Cat #PM-WCPV-S-1; Delta, JPT cat# PM-SARS2-SMUT06-1) is a total of 315 spike peptides split into two pools, S1 and S2, comprised of 158 and 157 peptides each. The N peptide pool (JPT; Cat # PM-WCPV-NCAP-1) was also used to stimulate cells. A SIV-Nef peptide pool

(BEI Resources) was used as an off-target negative control. Stimulated splenocytes were then stained with a fixable cell viability stain (eBioscience™ Fixable Viability Dye eFluor™ 506 Cat# 65-0866-14) followed by the lymphocyte surface markers CD8β and CD4, fixed with CytoFix (BD), permeabilized, and stained for intracellular accumulation of IFN-γ, TNF-α and IL-2. Fluorescent-conjugated anti-mouse antibodies used for labeling included CD8β antibody (clone H35-17.2, ThermoFisher), CD4 (clone RM4-5, BD), IFN-γ (clone XMG1.2, BD), TNF-α (clone MP6-XT22, BD) and IL-2 (clone JES6-5H4; BD), and staining was performed in the presence of unlabeled anti-CD16/CD32 antibody (clone 2.4G2; BD). Flow cytometry was performed using a Beckman-Coulter Cytoflex S flow cytometer and analyzed using Flowjo Software.

ELISpot assay

ELISpot assays were used to detect cytokines secreted by splenocytes from inoculated mice. Fresh splenocytes were used on the same day as harvest, and cryopreserved splenocytes containing lymphocytes were used the day of thawing. The cells ($2-4 \times 10^5$ cells per well of a 96-well plate) were added to the ELISpot plate containing an immobilized primary antibody to either IFN-γ or IL-4 (BD Cat# 551881 and BD Cat# 551878, respectively), and were exposed to various stimuli (e.g. control peptides SIV and ConA, S-WT and N peptides pools – see catalog numbers above) at a concentration of 1-2 μg/mL peptide pools for 36-40 hours. After aspiration and washing to remove cells and media, extracellular cytokine was detected by a biotin-conjugated secondary antibody to cytokine conjugated to biotin (BD), followed by a streptavidin/horseradish peroxidase conjugate was used detect the biotin-conjugated secondary antibody. The number of spots per well, or per $2-4 \times 10^5$ cells, was counted using an ELISpot plate reader. Quantification of Th1/Th2 bias was calculated by dividing the IFN-γ spot forming cells (SFC) per million splenocytes with the IL-4 SFC per million splenocytes for each animal.

ELISA for detection of antibodies

For IgG antibody detection in inoculated mouse sera and lung homogenates, ELISAs for spike-binding (including S1 Delta) and nucleocapsid-binding antibodies and IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3) were used. A microtiter plate was coated overnight with 100 ng of either purified recombinant SARS-CoV-2 S-FTD (FL S with fibrin trimerization domain, constructed and purified in-house by ImmunityBio), purified recombinant Spike S1 domain (S1(wt)) (Sino; Cat # 40591-V08B1), purified recombinant Delta variant Spike S1 domain (S1(Delta)) (Sino; Cat # 40591-V08H23), or purified recombinant SARS-CoV-2 nucleocapsid (N) protein (Sino; Cat # 40588-V08B) in 100 μ L of coating buffer (0.05 M Carbonate Buffer, pH 9.6). The wells were washed three times with 250 μ L PBS containing 1% Tween 20 (PBST) to remove unbound protein and the plate was blocked for 60 minutes at room temperature with 250 μ L PBST. After blocking, the wells were washed with PBST, 100 μ L of either diluted serum or diluted lung homogenate samples was added to each well, and samples incubated for 60 minutes at room temperature. After incubation, the wells were washed with PBST and 100 μ L of a 1/5000 dilution of anti-mouse IgG HRP (GE Health Care; Cat # NA9310V), anti-mouse IgG₁ HRP (Sigma; Cat # SAB3701171), anti-mouse IgG_{2a} HRP (Sigma; Cat # SAB3701178), anti-mouse IgG_{2b} HRP (Sigma; catalog# SAB3701185), anti-mouse IgG₃ HRP conjugated antibody (Sigma; Cat # SAB3701192), or anti-mouse IgA HRP conjugated antibody (Sigma; Cat # A4789) was added to wells. For positive controls, 100 μ L of a 1/5000 dilution of rabbit anti-N IgG Ab or 100 μ L of a 1/25 dilution of mouse anti-S serum (from mice immunized with purified S antigen in adjuvant) were added to appropriate wells. After incubation at room temperature for 1 hour, the wells were washed with PBS-T and incubated with 200 μ L o-phenylenediamine-dihydrochloride (OPD) substrate (Thermo Scientific Cat # A34006) until appropriate color development. The color

reaction was stopped with addition of 50 μ L 10% phosphoric acid solution (Fisher Cat # A260-500) in water and the absorbance at 490 nm was determined using a microplate reader (SoftMax Pro, Molecular Devices).

Calculation of relative ng amounts of antibodies and the Th1/Th2 IgG subclass bias

A standard curve of IgG for OD vs. ng mouse IgG was generated using purified mouse IgG (Sigma Cat #15381; absorbance values were converted into mass equivalents for both anti-S and anti-N antibodies. Using these values, we calculated the geometric mean value for S- and N-specific IgG per milliliter of serum induced by vaccination. These values were also used to quantify the Th1/Th2 bias for the humoral responses by dividing the sum total of Th1 biased antigen-specific IgG subclasses (IgG2a, IgG2b and IgG3) with the total Th2 skewed IgG3, for each mouse. For mice that lack anti-S and/or anti-N specific IgG responses, Th1/Th2 ratio was not calculated. Conversely, some responses, particularly for anti-N responses in IgG2a and IgG2b (both Th1 biased subclasses), were above the limit of quantification with OD values higher than those observed in the standard curve. These data points were reduced to values within the standard curve, and thus will reflect a lower Th1/Th2 bias than would otherwise be reported.

Endpoint titers

Serial dilutions were prepared from each serum sample, with dilution factors ranging from 400 to 6,553,600 in 4-fold steps. These dilution series were characterized by whole IgG ELISA assays against both recombinant S1(wt) and recombinant S1(Delta), as described above. Half maximal response values (Ab_{50}) were calculated by non-linear least squares fit analysis on the values for each dilution series against each recombinant S1 in GraphPad Prism. Serum samples from mice without anti-S responses were removed Ab_{50} , μ g IgG/mL sera, and endpoint titer analyses and reported as N/D on the graphs. Endpoint titers were defined as the last dilution with

an absorbance value at least 3 standard deviations higher than the standard deviation of all readings from serum of untreated animals (n = 32 total negative samples). Quantitative titration values (μg IgG/mL sera) were calculated against a standard curve as described above.

Pseudovirus neutralization assay

SARS-CoV-2 pseudovirus neutralization assays were conducted on immunized mouse serum samples using procedures adapted from Crawford *et al.*, 2020.³⁴ In brief, lentiviral pseudoviruses expressing SARS-CoV-2 spike protein variants were prepared by co-transfecting HEK293 cells (ATCC CRL-3216) with a plasmid containing a lentiviral backbone expressing luciferase and ZsGreen (BEI Resources NR-52516), plasmids containing lentiviral helper genes (BEI Resources NR-52517, NR-52518, NR-52519), and a delta19 cytoplasmic tail-truncated SARS-CoV-2 spike protein expression plasmid (Wuhan strain, B.1.1.7, and B.1.351 spike variant plasmids were a gift from Jesse Bloom of Fred Hutchinson Cancer Research Center; B.1.617.2 “delta” variant plasmid a gift from Thomas Peacock of Imperial College London). Pseudovirus stocks were harvested from the cell culture media after 72 hours of incubation at 37°C, 5% CO₂, filtered through a 0.2 μm filter, and frozen until use.

Mouse serum samples were diluted 1:10 in media (Gibco DMEM + GlutaMAX + 10% FBS) and then serially diluted 1:2 for 11 total dilutions, and incubated with polybrene (Sigma) and pseudovirus for 1 hour at room temperature. Serum-virus mix was then added in duplicate to seeded hACE2 expressing HEK293 cells (BEI Resources) and incubated at 37°C, 5% CO₂ for 72 hours. To determine 50% inhibitory concentration (IC₅₀) values, plates were scanned on a high content fluorescent imager (Molecular Devices ImageXpress Pico) for ZsGreen expression. Total integrated intensity per well was used to calculate % pseudovirus inhibition noted in each well.

Neutralization curves were fit with a four-parameter sigmoidal curve which was used to calculate IC50 values.

Statistical analyses and graph generation

All statistical analyses were performed and graphs generated used in figures were generated using GraphPad Prism software. Statistical tests for each graph are described in the figure legends. Statistical analyses of Endpoint Titer for anti-S1 IgG (Figure 4) was performed by assignment of a value of 200 – one half the Level of Detection (LOD) of 400 – to the 4 animals with serum values below the LOD.

RESULTS

The SASA S vaccine enhanced generation of anti-S(wt) IgG

Mice receiving the SASA S vaccine in any homologous or heterologous vaccination regimen had the highest levels of anti-full length S(wt) (FL S) IgG2a and 2b as determined by OD at 490 nm in ELISA (Fig. 3A). As expected, only mice receiving the N antigen generated anti-N IgG (also determined by OD at 490 nm in ELISA), which was similar for all groups receiving an N-containing antigen (Fig. 3B) by AdS+ N homologous, prime, or boost vaccination. Determination of the IgG1/IgG2a + IgG2b + IgG3 ratio using ng amounts calculated from the OD reading (see *Methods*) revealed responses were highly T helper cell 1 (Th1)-biased, with all calculated values being greater than one (Fig. 3C).

Fig. 3 Anti-full length (FL) spike wild type (Swt) and -nucleocapsid (N) IgG antibody levels in sera show T helper cell 1 (Th1) bias. (A) Levels of anti-FL Swt and (B) anti-N IgG1, IgG2a, IgG2b and IgG3 subtypes represented by OD at 490 nm from ELISA of sera are shown. Statistical analyses performed using one-way ANOVA and Tukey's post-hoc comparison of all groups to all other groups with the exception of comparison to the SASA S > group t SASA S hat did not receive an N antigen for anti-N IgG; where * $p \leq 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. (C) The IgG1/IgG2a+IgG2b+IgG3 ratio calculated using the ng equivalents for each is shown with a dashed line at 1. Values > 1 reflect Th1 bias. The number (n) of animals in which the ratio was not determined due to very low antibody levels is shown below the x-axis for each group. The homologous SASA S group did not receive an N antigen. Data graphed as the mean and SEM. The legend in C applies to all figure panels.

Humoral responses against wildtype and Delta S1 were similar in all SASA S groups

To assess serum antibody production specific for delta B.1.617.2 variant as compared to wild type S, an ELISAs were performed using either the wt or B.1.617.2 sequence S1 domain of S, which contains the RBD.

Vaccine regimens including the SASA S vaccine elicited the highest anti-S1(wt) and S1(Delta) responses as represented by the Ab₅₀, µg IgG/mL, and endpoint titers (Fig. 4A, B, and C, respectively). Four of seven AdS+N homologous vaccinated mice had serum IgG levels against

these antigens that were below the level of detection. Overall, the mean antibody titers for SASA S homologous and SASA S > AdS+N groups were highest. For Ab₅₀ and µg IgG/mL (Fig. A and B) statistical comparison of the AdS+N group to other groups was not performed because of the presence of values below the LOD in the AdS+N group. For endpoint titer (Fig. 4C), the only significant difference was observed between AdS+N homologous versus SASA S homologous vaccination for anti-S1(delta) IgG, with the caveat that for this statistical analysis, serum values of 200 for those animals with IgG below the LOD of 400 were used.

Fig. 4 Wildtype and B.1.617.2 'Delta' S1-specific IgG endpoint titers. Levels of anti-S1(wt) and -Delta S1 IgG are shown by (A) Ab₅₀ reciprocal dilution, (B) µg/mL sera, and (C) endpoint titer reciprocal dilution. Values were below the level of detection in 4 of 7 AdS+N homologous group mice. Statistical analyses performed using one-way ANOVA and Tukey's post-hoc comparison of all groups for anti-S1 (WT) or -S1 (Delta) for (C) only where * p = 0.0333; sera without detectable levels of anti-S1 IgG were assigned a value of 200, one-half the Limit of Detection (LOD) of 400. Data graphed as the mean and SEM. The legend in C applies to all figure panels.

An AdS+N boost after SASA S prime vaccination enhances CD4+ and CD8+ T cell responses

Significantly higher percentages of CD4+ T-cells from SASA S > AdS+N group mice secreted IFN- γ alone, IFN- γ and tumor necrosis factor- α (TNF- α), or IFN- γ , TNF- α , and interleukin-2 (IL-2) as detected by intracellular cytokine staining (ICS) in response to S(wt) peptides as compared to both the AdS+N or SASA S homologous groups (Fig. 5A, C, and D). Additionally, the mean percentages were significantly higher than that of the AdS+ N > SASA S group.

The enhancement of cytokine production by AdS+N boost of an SASA S prime was even more pronounced for CD8+ T cells (Fig. 5B, D, and F). Cytokine production was significantly higher in the SASA S > AdS+N group compared to both the homologous vaccination groups as well as the AdS+N > SASA S group.

As expected, only T cells from mice receiving vaccination regimens that included delivery of the N antigen by the AdS+N vaccine produced cytokines in response to N peptide stimulation. Mean responses of both CD4+ and CD8+ T cells to N peptides were similar for groups receiving AdS+N as a boost, either as part of homologous or heterologous vaccination (Figure 5A-F).

Fig. 5 CD4⁺ and CD8⁺ T cell Intracellular cytokine staining (ICS) in response to S(wt) and N peptides. (A, B) ICS for interferon- γ (IFN- γ), (C, D) IFN- γ and tumor necrosis factor- α (TNF- α), and (E, F) IFN- γ , TNF- α and interleukin-2 (IL-2) are shown for CD4⁺ and CD8⁺ T cells, respectively. Statistical analyses performed using one-way ANOVA and Tukey's post-hoc comparison of all groups to all other groups with the exception of comparison to the SASA S > SASA S group that did not receive an N antigen (comparisons to UnTx > UnTx are shown); where * $p \leq 0.05$, ** $p < 0.01$, and *** $p < 0.001$. Data graphed as the mean and SEM. The legend in A applies to all figure panels.

CD4⁺ and CD8⁺ T-cell production of IFN- γ was similar in response to either S(wt) or S(Delta) peptides

CD4⁺ and CD8⁺ T cells show similar levels of IFN- γ production in ICS in response to either S(wt) or S(Delta) sequence peptides (Fig. 6A and B, respectively). Patterns of CD4⁺ and CD8⁺

T-cell stimulation by S protein peptides between the vaccination regimens were also similar between the S(wt) and S(Delta) peptides. Compared to the untreated control, the significance of the increase in IFN- γ production was again the highest for the SASA S > AdS+N group for both CD4⁺ and CD8⁺ T cells, and in response to either S(wt) or S(Delta) peptides.

Fig. 6 CD4⁺ and CD8⁺ T-cell responses to S(wt) and S(Delta) peptides are similar. Both CD4⁺ (A) and CD8⁺ (B) T cells show similar levels of interferon- γ (IFN- γ) production in ICS in response to either S(wt) or S(Delta) sequence peptides. For both T-cell types, the greatest responses were seen with SASA S > AdS+N vaccination. Statistical analyses performed using one-way ANOVA and Tukey's post-hoc comparison of all groups to all other groups; where * $p \leq 0.05$ and ** $p < 0.01$. Data graphed as the mean and SEM. The legend in A applies to all figure panels.

Numbers of IFN- γ -secreting splenocytes were the highest from mice receiving SASA S >

AdS+N heterologous vaccination

As shown in Figure 7A, ELISpot detection of cytokine secretion in response to the S peptide pool revealed that animals receiving heterologous SASA S > AdS+N vaccination developed significantly higher levels of S peptide-reactive IFN- γ -secreting T cells than all other groups except the SASA S homologous group (which had a lower mean). Numbers of IFN- γ -secreting T cells in response to the N peptide pool were similar for AdS+N homologous and SASA S > AdS+N groups. T cells from SASA S > SASA S group animals did not secrete IFN- γ in response to the N peptide pool, as expected, because the SASA S vaccine does not deliver the N antigen. While the difference was not significant due to individual variation, the mean number of N-reactive

stimulated cells secreting IFN- γ due to AdS+N > SASA S vaccination was lower than the other groups receiving a vaccine with N.

Induction of interleukin-4 (IL-4) secreting T cells was low for all animals in all groups (Fig. 7B), therefore the IFN- γ /IL-4 ratio was above 1 for all animals for which the ratio could be calculated (Fig. 7C), reflecting the Th1-bias of all T-cell responses.

Fig. 7 Heterologous vaccination increases T-cell cytokine secretion in ELISpot. (A) Numbers of interferon- γ (IFN- γ) and (B) interleukin-4 (IL-4) secreting T cells in response to S WT and N peptides pools. (C) The IFN- γ /IL-4 ratio; value of 1 indicated by dashed line. The ratio was not determined (ND) for animals with very low IL-4 secretion. Statistical analyses performed using one-way ANOVA and Tukey's post-hoc comparison of all groups to all other groups where *p $\leq$ 0.05 and **p < 0.01. Data graphed as the mean and SEM. The legend in C applies to all figure panels.

Sera from mice receiving the SASA S vaccine neutralize Wuhan, Delta, and Beta pseudoviruses

Sera from the homologous SASA S group and both heterologously vaccinated groups neutralized Wuhan (D614G), Delta (B.1.617.2), and Beta (B.1.351) pseudoviruses, as shown in

Figure 8. Sera from AdS+N homologous mice showed lower neutralization capability for all strains. Neutralization of Wuhan strain pseudovirus by sera from SASA S homologous and SASA S > AdS+N heterologous group mice was significantly greater than that from AdS+N > SASA S mice, but there were no statistical differences among these 3 groups for the Delta or Beta strains.

Fig. 8 Sera from SASA S > AdS+N heterologously vaccinated mice neutralizes Wuhan, Delta, and Beta strain SARS-CoV-2 pseudovirus. Neutralization of Wuhan strain pseudovirus by sera from SASA S homologous and SASA S > AdS+N mice was significantly greater than that for AdS+N > SASA S mice (as well as untreated and AdS+N homologous). There were no significant differences between the SASA S homologous and the two heterologous groups for the Delta or Beta strain pseudoviruses. Statistical comparison of IC50 values for untreated and AdS+N homologous group mice with all/many values < the LOD was not performed. Statistical analyses performed using one-way ANOVA and Tukey's post-hoc comparison of SASA S homologous, AdS+N > SASA S, and SASA S > AdS+N groups to each other for each strain where * $p \leq 0.05$ and ** $p < 0.01$; and for the same group for each different strain. Data graphed as the mean and SEM.

DISCUSSION

The immune responses observed in the present study support our hypothesis that heterologous vaccination provides an opportunity for increased humoral and cell-mediated responses. These results and hypothesis are consistent with recently-published data supporting enhanced antibody responses in patients who received heterologous vaccination with the currently-FDA authorized COVID-19 vaccines.³⁵ Delivery of the SASA S vaccine elicited higher anti-S IgG than the AdS+N vaccine, but the AdS+N vaccine provided the N antigen that broadened humoral responses and

thus the potential to enhance protection against future SARS-CoV-2 variants of concern that could emerge. We note that mean anti-N IgG responses, while not statistically different among groups that received the N antigen (not SASA S homologous) were, as predicted, highest with homologous AdS+N vaccination.

Perhaps the most striking finding in the present study are the enhanced responses of S-specific CD4⁺ and CD8⁺ T-cells in SASA S > AdS+N group mice, an effect that was most pronounced for CD8⁺ T cells. The similarity of responses of CD4⁺ and CD8⁺ T cells to either S(wt) or S(Delta) suggest this vaccine regimen has a high probability of conferring T-cell mediated protection against the highly transmissible Delta variant in addition to humoral protection.

Immune responses elicited by SASA S > AdS+N vaccination were consistently the highest of the groups tested (although not always significantly so) and we hypothesize that because the SASA S vaccines elicits the greatest humoral response to S when given in any order – possibly reaching the upper detection limit for our ELISA - it enhances CD4⁺ T-cell activation as these are closely related to humoral/B cell responses. Therefore, CD4⁺ T-cell activation might be expected to be higher after a boost if there are stronger pre-existing, prime-induced B cell responses, that is, when SASA S is the prime. Adenovirus vectors such as that used for the AdS+N vaccine are good at eliciting CD8⁺ T-cell responses, which we posit explains why CD8⁺ T-cell responses are only slightly lower for homologous AdS+N vaccination (despite antibody and CD4⁺ T-cell responses being lower), as compared to heterologous vaccination. CD8⁺ T-cell responses likely also benefit from more robust pre-existing CD4⁺ T-cell and B cell responses, a condition that exists most prominently when the SASA S vaccine is given as the prime. Effectively, enhanced CD4⁺-specific T-helper responses seen with SASA S prime dosing might have provided conditions for the

enhanced CD8⁺ specific response upon AdS+N boost. The confirmation of this hypothesis awaits further investigation.

Importantly, all of the vaccination regimens that included the SASA S vaccine neutralized pseudovirus effectively, reflecting the strength of humoral responses to the SASA S vaccine. This does not however indicate that the predominantly T-cell inducing AdS+N vaccine would not be effective in an *in vivo* model of SARS-CoV-2 challenge; in fact, we have previously reported that homologous AdS+N prime-boost vaccination of non-human primates confers protection against viral challenge ⁶. In the *in vivo* viral challenge testing paradigm, cell-mediated immunity (not accessed in the pseudovirus assay) conferred by AdS+N vaccination likely plays a key role in protection, as has been reported for natural infection of patients. ³⁶⁻³⁹

The findings here, including cross-reactive humoral and T-cell responses to S Delta and - for regimens including SASA S – neutralization of Wuhan, Delta, and Beta pseudovirus, support ongoing studies of heterologous vaccination with the SASA S and AdS+N vaccines. Further testing in pre-clinical models of SARS-CoV-2 challenge and clinical trials should be conducted to assess the capability of this vaccine regimen to provide increased protection against COVID-19 and SARS-CoV-2 variants by combining the ability of SASA S to elicit vigorous humoral responses with AdS+N's second, highly antigenic N antigen and T-cell response enhancement.

REFERENCES

1. Polack FP, Thomas SJ, Kitchin N, et al: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 383:2603-2615, 2020
2. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nat Med* 27:270-278, 2021
3. Shinde V, Bhikha S, Hoosain Z, et al: Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* 384:1899-1909, 2021
4. Sadoff J, Gray G, Vandebosch A, et al: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 384:2187-2201, 2021
5. Voysey M, Clemens SAC, Madhi SA, et al: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* 397:99-111, 2021
6. Gabitzsch E, Safrit JT, Verma M, et al: Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. *Front Immunol* 12:10.3389/fimmu.2021.729837, 2021
7. Rice A, Verma M, Shin A, et al: Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. *Sci Rep* 11:14917, 2021
8. Sieling P, King T, Wong R, et al: Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants. *medRxiv* 2021.04.05.21254940, 2021
9. Niazi KR, Ochoa M-T, Sieling PA, et al: Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences. *Immunology* 122:522-531, 2007
10. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. *Cancer Res* 56:21-6, 1996
11. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al: Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. *Proc Natl Acad Sci USA* 92:11671-5, 1995
12. Voigt EA, Gerhardt A, Hanson D, et al: A long-term thermostable self-amplifying RNA vaccine against COVID-19. Manuscript in preparation, 2021
13. Spencer AJ, McKay PF, Belij-Rammerstorfer S, et al: Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. *Nat Commun* 12:2893, 2021
14. Wu L, Kong WP, Nabel GJ: Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. *J Virol* 79:8024-31, 2005
15. Casper C: New Technologies for Accessible, Durable and Broadly Protective Coronavirus Vaccines IDRI http://www.idri.org/wp-content/uploads/2021/04/IDRI-Technologies_Coronavirus.pdf:1-15, 2021

16. Erasmus JH, Khandhar AP, Guderian J, et al: A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. *Mol Ther* 26:2507-2522, 2018
17. Bloom K, van den Berg F, Arbuthnot P: Self-amplifying RNA vaccines for infectious diseases. *Gene therapy* 28:117-129, 2021
18. Sandbrink JB, Shattock RJ: RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics? *Front Immunol* 11:10.3389/fimmu.2020.608460, 2020
19. Zhang C, Maruggi G, Shan H, et al: Advances in mRNA Vaccines for Infectious Diseases. *Front Immunol* 10:594, 2019
20. Zhang L, Jackson CB, Mou H, et al: SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. *Nat Commun* 11:6013, 2020
21. Weissman D, Alameh M-G, de Silva T, et al: D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. *Cell host & microbe* 29:23-31.e4, 2021
22. Kirchdoerfer RN, Wang N, Pallesen J, et al: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. *Sci Rep* 8:15701-15701, 2018
23. Bangaru S, Ozorowski G, Turner HL, et al: Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. *Science* 370:1089-1094, 2020
24. van Doremalen N, Lambe T, Spencer A, et al: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature* 586:578-582, 2020
25. Zhu F-C, Li Y-H, Guan X-H, et al: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *The Lancet* 395:1845-1854
26. Amalfitano A, Begy CR, Chamberlain JS: Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. *Proc Natl Acad Sci USA* 93:3352-3356, 1996
27. Amalfitano A, Chamberlain JS: Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. *Gene Ther* 4:258-63, 1997
28. Amalfitano A, Hauser MA, Hu H, et al: Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted. *J Virol* 72:926, 1998
29. Seregin SS, Amalfitano A: Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. *Expert Opin Biol Ther* 9:1521-31, 2009
30. Voigt EA, Fuerte-Stone J, Granger B, et al: Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus. *Mol Ther* 29:2782-2793, 2021
31. Erasmus JH, Archer J, Fuerte-Stone J, et al: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection. *Mol Ther Methods Clin Dev* 18:402-414, 2020
32. Gerhardt A, Voigt E, Archer M, et al: A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response. *bioRxiv*:2021.02.01.429283, 2021
33. Skordos I, Demeyer A, Beyaert R: Analysis of T cells in mouse lymphoid tissue and blood with flow cytometry. *STAR protocols* 2:100351-100351, 2021

34. Crawford KHD, Eguia R, Dingens AS, et al: Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* 12:513, 2020
35. Atmar RL, Lyke KE, Deming ME, et al: Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report. *medRxiv*:2021.10.10.21264827, 2021
36. Grifoni A, Sidney J, Vita R, et al: SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. *Cell Host Microbe* 29:1076-1092, 2021
37. Tarke A, Sidney J, Kidd CK, et al: Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Rep Med* 2:100204, 2021
38. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell* 183:158, 2020
39. Tan AT, Linster M, Tan CW, et al: Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep* 34:108728, 2021